Prelude Capital Management, LLC Avrobio, Inc. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $12,600 - $22,344	-16,800 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $4,515 - $14,140	-3,500 Reduced 17.24%	16,800 $22,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $70,035 - $122,815	20,300 New	20,300 $78,000
Q4 2020 Feb 16, 2021	SELL	$12.79 - $17.1 $1,279 - $1,710	-100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$12.99 - $19.41 $1,299 - $1,941	100 New	100 $1,000

Q3 2019 Nov 14, 2019	SELL	$14.12 - $23.44 $6,099 - $10,126	-432 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$13.21 - $27.29 $5,706 - $11,789	432 New	432 $7,000
Q4 2018 Feb 14, 2019	SELL	$15.43 - $32.7 $200,481 - $424,871	-12,993 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$26.95 - $52.7 $350,161 - $684,731	12,993 New	12,993 $674,000

28.1M

100

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.